ClinicalTrials.gg
TerminatedNCT06617429AspireUpdated Nov 3, 2026

Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

A Phase 3 interventional study of GTX-102 and Sham-LP in Angelman Syndrome, sponsored by Ultragenyx Pharmaceutical Inc. Terminated at 28 sites in 6 countries. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Ultragenyx Pharmaceutical Inc · Phase 3, Interventional, and Treatment

Why this study was terminated
Lack of efficacy
Updated Nov 3, 2026Now TerminatedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Angelman Syndrome with a site in United States — 6 open to participants now, 10 under way, 3 of them phase 3. Angelman Syndrome · United States.

Enrollment
4th of 24
129 · median 73
Started
2024
with 1 other
Phase 3
8 of 33
2 open now
Registered
27th of 33
by date
Lead sponsor
4 of 33
Ultragenyx Pharmaceutical Inc

Among the 33 studies in Angelman Syndrome with a site in United States, this one is the 4th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2024, is one of 8 in phase 3, and was the 27th registered.

Angelman Syndrome

52 studies on the registry are indexed under Angelman Syndrome; 16 are open to participants now.

Browse Angelman Syndrome studies →

Open to participants now

6 of the 33 studies in Angelman Syndrome with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Angelman Syndrome studies recruiting now, 6 (43%) set no upper age limit and 7 (50%) stop at 75 or younger; 14 take children under 18; none take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Angelman Syndrome with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with deletion-type Angelman Syndrome (AS).

03

Conditions studied

  • Angelman Syndrome

Browse trials for

Keywords

  • Angelman Syndrome
04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Signed from parent(s) or legal guardian(s)
  • Confirmed diagnosis of AS with genetic confirmation of full maternal ubiquitin-protein ligase E3A (UBE3A) gene deletion causing AS in the region of 15q11.2 q13
  • Able to ambulate independently, or with assistance at the Screening Visit (note, a child whose primary means of mobility is by wheelchair is excluded from the study)
  • count, / international normalized ratio, and partial thromboplastin time within 1.5x the normal limits at the Screening Visit
  • Willing and able to comply with scheduled visits, drug administration plan, laboratory tests, and all study procedures, including LP procedure, MRI, and tolerating anesthesia without intubation
  • From the time of informed consent through to at least 6 months after the final dose of GTX-102, females of who are sexually active must use highly effective or abstinence. Males are able to participate if they agree to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the study and for at least 3 months after the final dose of GTX-102

Key Exclusion Criteria:

  • Any change in medications or diet/supplements intended to treat symptoms of AS (eg, sleeping aids, antiseizure medications, supplements, dietary change including ketogenic or low-glycemic index diet, other) within the month prior to the Screening Visit (excluding weight-based adjustments)
  • Any condition that creates an increased risk of unsuccessful LP
  • Current or expected concomitant use of drugs that increase the risk of bleeding (eg, heparin, low molecular weight heparin, platelet inhibitors)
  • Known to GTX-102 or its that, in the judgment of the Investigator, places the subject at increased risk for adverse effects
  • Presence or history of any condition, lab abnormality, or infection, that, in the judgement of the Investigator, would interfere with participation, pose undue safety risk, or would confound interpretation of results
  • Pregnant or breastfeeding or planning to become pregnant (self or partner) at any time during the study
  • Use of any product or investigational medical device within 6 months or 5 half-lives prior to the Screening Visit or any prior use of gene therapy or ASO regardless of duration since last administration
  • Concurrent participation in any interventional study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    GTX-102

    Participants will receive GTX-102 via lumbar puncture (LP) during both the double-blind and open-label period

    Drug: GTX-102

  • Sham comparator
    Sham-LP then GTX-102

    Participants will receive sham procedure during the double-blind period and then will receive GTX-102 via LP during the open-label period

    Drug: GTX-102 · Procedure: Sham-LP

Interventions

  • antisense oligonucleotide

    Also known as: apazunersen

  • ProcedureSham-LP

    Small needle prick on the lower back at the location where the LP injection is normally made

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Bayley-4 Cognitive Raw Score Without Caregiver Input at Day 338

    Time frame: Baseline, Day 338

Secondary outcomes

  1. Net Response in Multidomain Responder Index (MDRI)

    Time frame: Day 338

  2. Change from Baseline in ABC-C Hyperactivity/Noncompliance Subscale Score at Day 338

    Time frame: Baseline, Day 338

  3. Change from Baseline in Bayley-4 Receptive Communication Raw Score at Day 338

    Time frame: Baseline, Day 338

  4. Change from Baseline in Angelman Severity Assessment (ASA) Sleep Rating Raw Score at Day 338

    Time frame: Baseline, Day 338

  5. Change from Baseline in Vineland Adaptive Behavior Scales-3 (Vineland-3) Receptive Communication Raw Score at Day 338

    Time frame: Baseline, Day 338

  6. Change from Baseline in Vineland-3 Expressive Communication Raw Score at Day 338

    Time frame: Baseline, Day 338

  7. Change from Baseline in Bayley-4 Gross Motor Raw Score at Day 338

    Time frame: Baseline, Day 338

  8. Change from Baseline in ASA Gross Motor Rating at Day 338

    Time frame: Baseline, Day 338

  9. Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), Severity of AEs and Relationship to Investigational Drug, Procedure, and Premedication

    Time frame: 2 Years

07

Study locations

28 sites
  • Cedars Sinai
    Los Angeles, California 90048, United States
  • UCSD, Rady Children's Hospital
    San Diego, California 92123, United States
  • UCSF
    San Francisco, California 94143, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
  • Rare Disease Research
    Atlanta, Georgia 30329, United States
  • Rush University
    Chicago, Illinois 60612, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Children's Mercy
    Kansas City, Missouri 64108, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • UNC Chapel Hill Pediatrics
    Chapel Hill, North Carolina 27599, United States
  • Rare Disease Research
    Hillsborough, North Carolina 27278, United States
  • The University of Texas
    Austin, Texas 78723, United States
  • Carum Research Inc
    Dallas, Texas 75243, United States
  • McGill University Health Centre
    Montreal, Quebec H4A3J1, Canada
  • British Columbia Children's Hospital
    Vancouver, V6H 3V4, Canada
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20251, Germany
  • University of Leipzig
    Leipzig, 04155, Germany
  • Haunersche Kinderklinik
    Munich, 80336, Germany
  • Nagoya City University Graduate School of Medical Sciences
    Nagoya, Aichi-ken 467-0001, Japan
  • Osaka City General Hospital
    Osaka, 543-0021, Japan
  • Hokkaido University Hospital
    Sapporo, 060-8648, Japan
  • Medical University of Gdańsk
    Gdansk, 80211, Poland
  • Polish Mothers Memorial Institute
    Lodz, 93-338, Poland
  • Hospital Universitario Parc Tauli
    Barcelona, 08208, Spain
  • Hospital Sant Joan de Deu
    Barcelona, 08950, Spain
  • Hospital Universitario Puerta de Hierro
    Madrid, 28222, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, 41013, Spain
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2024 to primary completion in Jul 2026, 19 months.

Completion moved once since we started tracking on Sep 25, 2026: Nov 2027 → Oct 2026, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2024
First posted
Sep 27, 2024
StartActual
Dec 3, 2024
Primary completionActual
Jul 10, 2026
CompletionActual
Oct 30, 2026was Nov 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Lack of efficacy
changed Nov 3, 2026
Study completion
Nov 2027→Oct 30, 2026 (actual)
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Active, not recruiting→Terminated
    Why stopped Lack of efficacy
    Study completion Nov 2027→Oct 30, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06617429
Responsible party
Sponsor
First posted
Sep 27, 2024
Start date
Dec 3, 2024
Primary completion
Jul 10, 2026
Completion
Oct 30, 2026
Last update
Nov 3, 2026

Study contacts

Medical Director
study director · Ultragenyx Pharmaceuticals Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apazunersen sodium

Start the discussion